use of Exercise for Treatment of Chronic Fatigue Syndrome
Tóm tắt
Chronic fatigue syndrome (CFS) is a condition that results in moderate to severe disability, the primary feature of which is fatigue of unknown origin. There is a lot of interest in classifying, characterising and treating patients with CFS. Currently, the two major theories of a medical cause of CFS are viral infection and immune dysregulation. Patients report critical reductions in levels of physical activity, and many experience ‘relapses’ of severe symptoms following even moderate levels of exertion. Despite this, most studies report CFS patients to have normal muscle strength and either normal or slightly reduced muscle endurance. Histological and metabolic studies report mixed results: CFS patients have either no impairment or mild impairment of mitochondria and oxidative metabolism compared with sedentary controls. Current treatments for CFS are symptom-based, with psychological, pharmacological and rehabilitation treatments providing some relief but no cure. Immunological and nutritional treatments have been tried but have not provided reproducible benefits. Exercise training programmes are thought to be beneficial (if ‘relapses’ can be avoided), although few controlled studies have been performed. CFS is a long-lasting disorder that can slowly improve with time, but often does not. Further studies are needed to better understand the multiple factors that can cause chronic fatigue illness, as well as the effect that exercise training has on the symptoms of CFS.
Tài liệu tham khảo
Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991; 13 Suppl. 1: S8–11
Shorter E. Chronic fatigue in historical perspective. In Chronic fatigue syndrome. Ciba Foundation symposium no. 173 Chichester: Wiley and Sons, 1993: 6-22
Wessely S. History of postviral fatigue syndrome. Br Med Bul 1991; 47: 919–41
Wolfe F, Smythe HA, Aeons MB. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33: 160–72
Holmes GP, Kaplan JE, Schonberger LB, et al. Definition of the chronic fatigue syndrome [letter]. Ann Intern Med 1988; 109: 512
Schluederberg A, Straus SE, Peterson P, et al. Chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med 1992; 117: 325–31
Fukuda K, Straus SE, Hickie I, et al. Chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–8
Blondel-Hill E, Shafran SD. Treatment of the chronic fatigue syndrome: a review and practical guide. Drugs 1993; 46: 639–51
Lloyd AR, Hickie I, Boughton CR, et al. Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990a; 153: 522–8
Natelson BH, Ye N, Moul DE, et al. High titers of anti-Epstein-Barr virus DNA polymerase are found in patients with severe fatiguing illness. J Med Virol 1994; 42: 42–6
Edwards RHT, Gibson H, Clague JE, et al. Muscle histopathology and physiology in chronic fatigue syndrome. In: Bock GR, Whalan J, editors. Chronic fatigue syndrome. Ciba Foundation symposium no. 173. Chichester: John Wiley and Sons, 1993: 102–31
Kuratsune H, Yamaguti K, Takahashi M, et al. Acetylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18 Suppl. 1: S62–7
Bates DW, Buchwald D, Lee J, et al. A comparison of case definitions of chronic fatigue syndrome. Clin Infect Dis 1994; 181: S11–5
Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993; 153: 2759–65
Klimas N, Salvalo F, Morgan R, et al. Immunological abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403–10
Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active herpes virus type 6 infection. Ann Intern Med 1992; 116: 103–13
Keller RH, Lane JL, Klimas N, et al. Association between HLA class II antigens and the chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994; 18 Suppl. 1: S154–6
Straus SE, Fritz S, Dale JK, et al. Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 1993; 13: 30–40
Barker E, Fujimura SF, Fadem MB, et al. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18 Suppl. 1: S136–41
Wessely S, Chalder T, Hirsch S, et al. Postinfection fatigue: prospective cohort study in primary care. Lancet 1995; 345: 1333–8
Abbey SE, Garfinkel PE. Chronic fatigue syndrome and depression: cause, effect, or covariate. Rev Infect Dis 1991; 13 Suppl. 1: S73–83
Thase ME. Assessment of depression in patients with chronic fatigue syndrome. Rev Infect Dis 1991; 13 Suppl. 1: S114–8
Grafman J, Johnson R, Scheffers M. Cognitive and mood-state changes in patients with chronic fatigue syndrome. Rev Infect Dis 1991; 13 Suppl. 1: S45–50
Surawy C, Hackmann A, Hawton K, et al. Chronic fatigue syndrome: a cognitive approach. Behav Res Ther 1995; 33: 535–44
Petrie K, Moss-Morris R, Weinman J. The impact of catastrophic beliefs on functioning in chronic fatigue syndrome. J Psychosom Res 1995: 39; 31–7
Calabrese L, Davis ME, Wilke W. Chronic fatigue syndrome and a disorder resembling Sjogrens’s syndrome: preliminary report. Clin Infect Dis 1994; 18 Suppl. 1: S28–31
Komaroff AL. Clinic presentation of chronic fatigue syndrome. In: Bock GR, Whalan J, editors. Chronic fatigue syndrome. Ciba Foundation symposium no. 173. Chichester: John Wiley & Sons, 1993: 43–61
Noakes TD. Implications of exercise testing for prediction of athletic performance: a contemporary perspective. Med Sci Sports Exerc 1988; 20: 319–30
Sutton JR. VO2max — new concepts on an old theme. Med Sci Sports Exerc 1992; 24: 26–9
Wagner PD. Gas exchange and peripheral diffusion limitation. Med Sci Sports Exerc 1992; 24: 54–8
Kent-Braun J, Sharma KR, Weiner MW, et al. Central basis of muscle fatigue in chronic fatigue syndrome. Neurology 1993; 43: 125–31
Riley MS, Os’Brien CJ, McCluskey DR, et al. Aerobic work capacity in patients with chronic fatigue syndrome. BMJ 1990; 301: 953–6
Gibson H, Carroll N, Clague JE, et al. Exercise performance and fatigability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 993–8
Stokes MJ, Cooper RG, Edwards RHT. Normal muscle strength and fatigability in patient with effort syndromes. BMJ 1988; 297: 1014–7
Montague TJ, Marrie TJ, Bewick DJ, et al. Cardiac effects of common viral illnesses. Chest 1988; 94: 919–25
Skinner JS, Baldini FD, Gardner AW. Assessment of fitness. In: Bouchard C, Shepard RJ, Stephens T, et al., editors. Exercise, fitness, and health. Champaign (IL): Human Kinetics Publishers, 1990: 109–20
Lloyd AR, Phales J, Gandevia SC. Muscle strength, endurance and recovery in the post-infection fatigue syndrome. J Neurol Neurosurg Psychiatry 1988; 51: 1316–22
Lindh M, Johansson G, Hedberg M, et al. Studies on maximal voluntary contraction in patients with fibromyalgia. Arch Phys Med Rehab 1994; 75: 1217–22
Wong R, Lopachuk G, Zhu G, et al. Skeletal muscle metabolism in the chronic fatigue syndrome: in vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 1992; 102: 1716–22
Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy maximises sample size. Med Sci Sports Exerc 1982; 14: 101–2
Chance B, Eleff S, Leigh Jr JS, et al. Mitochondrial regulation of phosphocreatine/inorganic phosphate ratios in exercising human muscle: a gated 31-P NMR study. Proc Natl Acad Sci USA 1981; 78: 6714–8
Barnes PRJ, Taylor DJ, Kemp GJ, et al. Skeletal muscle bioenergetics in the chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 679–83
McCully KK, Vandenborne K, Posner JD. Magnetic resonance in physiology and medicine. In: Gillies R, editor. NMR in physiology and medicine. San Diego: Academic Press, Inc., 1994
Behan WMH, More IAR, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991; 83: 61–5
Byrne E, Trounce I, Dennett X. Chronic relapsing myalgia (? post viral): clinical histological and biochemical studies. Aust NZ J Med 1985; 15: 305–8
Byrne E, Trounce I. Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle. J Neurol Neurosurg Psychiatry 1987; 50: 743–6
Arnold DL, Radda GK, Bore PJ, et al. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. Lancet 1984; i: 1367–9
McCully K, Natelson B, Sisto S-A, et al. Impaired phosphocreatine recovery in women with chronic fatigue syndrome. Med Sci Sports Exerc 1993; 25 Suppl.: S16
Bennett RM. Muscle physiology and cold reactivity in the fibromyalgia syndrome. Rheum Dis Clin North Am 1989; 15: 135–47
Lindh M, Johansson G, Hedberg M, et al. Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 1995; 24: 34–7
Bennett RM, Clark SR, Campbell SM, et al. Symptoms of Raynauds’s syndrome in patients with fibromyalgia. Arthritis Rheum 1991; 34: 264–9
Convertino V. Exercise and adaptation to microgravity environments. In: Fregly J, Blatteis C, editors. Handbook of physiology: adaptation to the environment. Bethesda (MD): American Physiological Society. In press
McCully KK, Kakihira H, Vandenborne K, et al. Noninvasive measurements of activity-induced changes in muscle metabolism. J Biomech 1991; 24 Suppl.: 153–62
Kent-Braun J, Sharma KR, Miller RG, et al. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle Nerve 1994; 17: 835–41
Vernikos J, Ludwig D. Intermittent gravity: how much, how often, and how long? Tech Memo no. 108800. Moffett Field (CA): NASA Ames Research Center, 1993
Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990; 82: 209–16
Jubrias SA, Bennett RM, Klug GA. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyaglia patients. Athritis Rheum 1994; 37: 801–7
Armstrong RB. Mechanisms of exercise-induced delayed onset muscular soreness: a brief review. Med Sci Sport Exerc 1984; 16: 529–38
Sisto SA. Chronic fatigue syndrome: an overview and intervention guidelines. Neurol Rep 1993; 17: 30–4
Lloyd AR, Gandevia S, Brockman A, et al. Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 1994; 18 Suppl. 1: S142–6
Newsholme EA, Parry-Billings M. Effects of exercise on the immune system. In: Bouchard C, Shepard RJ, Stephens T, editors. Physical activity, fitness, and health. Champaign (IL): Human Kinetics Publishers, 1994: 451–5
Gantz NM, Holmes GP. Treatment of patients with chronic fatigue syndrome. Drugs 1989; 38: 855–62
Sharpe MC. Follow-up of patients presenting with fatigue to an infectious disease clinic. BMJ 1992; 305: 147–52
Goldman JA. Hypermobilty and deconditioning: important links to fibromyalgia/fibrositis. South Med J 1991; 84: 1192
McCain GA, Bell DA, Mai FM, et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988; 31: 1135
Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. N Engl J Med 1988; 26: 1692–8
Lloyd AR, Hickie I, Wakefield D, et al. Placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. BMJ 1990b; 89: 561–8
Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double blind, placebo-controlled trial. Am J Med 1993; 94: 197–203
Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990; 89: 554–60
Cox IM, Campbell MJ, Dawson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991; 337: 557
Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Arch Intern Med 1989; 149: 2501–3
Kuragaki H, Yamaguchi K, Kitani T. Decrease in serum carnitine level of patients with chronic fatigue syndrome [summary report]. 2nd Meeting of the research committee on surveillance study of current CFS situations in japan and pathogenesis and clinical features of CFS: 1993 Mar 8; Tokyo, Japan, 1-7
Morris DH, Stark FJ. Unproven diet therapies in the treatment of the chronic fatigue syndrome. Arch Fam Med 1993; 2: 181–6
Wilson A, Hickie I, Lloyd A, et al. Longitudinal study of outcome of chronic fatigue syndrome. BMJ 1994; 308: 756–9
Kroenke K, Wood DO, Mangelsdorff AD. Chronic fatigue in primary care: prevalence, patient characteristics, and outcome. JAMA 1988; 260: 929–34
Clark MR, Katon W, Russo J, et al. Chronic fatigue: risk factors for symptom persistance in a 21/2 year follow-up study. Am J Med 1995; 98: 187–95
Hyde B, Bergmann S. Akureyri disease (myalgic encephalomyelitis), forty years later [letter]. Lancet 1988 Nov; 19: 1190–1
Deluca J, Johnson SK, Beldowicz D, et al. Neuropsychologic impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry 1995; 58: 38–43